Autoimmune diseases are becoming a global health problem and can be chronic and life-threatening. Statistics show that around 50 Mn in the U.S. itself suffer from autoimmune diseases.
This makes it all the more imperative to fast track their cure. Biocon is pioneering targeted therapies and exploring potential treatments to transform the breakdown of the body’s immunity into a breakthrough medical innovation
As one of the world’s largest producers of immunosuppressants, Biocon leverages its comprehensive portfolio of topical, systemic and biologic therapies to treat immune-mediated skin diseases like psoriasis, atopic dermatitis and vitiligo.
Itolizumab is the first biological drug for chronic plaque psoriasis, specially researched, developed and manufactured in India.
- Launched as ALZUMAb™ in India
- An approved ‘first-in-class’ therapy
- Binds to a specific molecule (CD6) on the surface of T cells to block their autoimmune activation, thereby preventing the formation of plaques
- An affordable biologic therapy with a less aggressive dosing regimen and a longer treatment free period